2008
A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells
Bonafé N, Rininger JA, Chubet RG, Foellmer HG, Fader S, Anderson JF, Bushmich SL, Anthony K, Ledizet M, Fikrig E, Koski RA, Kaplan P. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells. Vaccine 2008, 27: 213-222. PMID: 18996430, PMCID: PMC2651515, DOI: 10.1016/j.vaccine.2008.10.046.Peer-Reviewed Original ResearchConceptsVaccine candidatesClinical adverse effectsProtein vaccine candidateRecombinant vaccine candidateWNV vaccineAntibody titersHumoral immunityProtective efficacySafe vaccineWNV infectionChallenge modelVaccine antigensAnimal modelsViral protectionHigh dosesProtein antigensAdverse effectsImmunogenicitySerum-free cultureAntigenCell linesNaïve foalsVaccineAluminum hydroxideInfection
1995
Safety and Immunogenicity of an Outer Surface Protein A Vaccine in Subjects with Previous Lyme Disease
Schoen R, Meurice F, Brunet C, Cretella S, Krause D, Craft J, Fikrig E. Safety and Immunogenicity of an Outer Surface Protein A Vaccine in Subjects with Previous Lyme Disease. The Journal Of Infectious Diseases 1995, 172: 1324-1329. PMID: 7594671, DOI: 10.1093/infdis/172.5.1324.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, BacterialAntibody FormationAntigens, SurfaceBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferi GroupDose-Response Relationship, DrugEnzyme-Linked Immunosorbent AssayHumansImmunization ScheduleImmunoglobulin GLipoproteinsLyme DiseaseProspective StudiesSafetyVaccines, SyntheticConceptsSide effectsLyme diseaseOspA vaccinePrevious Lyme diseaseThree-dose scheduleLocal side effectsSystemic side effectsLyme vaccineMild arthralgiaVaccine doseThird doseProspective studyOspA antibodiesHealthy volunteersOuter surface proteinsVaccinePatientsDiseaseImmunogenicityDoseMonthsSubjectsSurface proteinsSafetyArthralgia